Diet and Weight Reducing Centers NAICS 812191

Mar 4, 2026 - Walgreens Expands Into Weight Management

• Walgreens’ launch of a virtual weight management program underscores the scale and shifting economics of the US diet and weight loss industry, according to MedCity News. Available in 28 states for adults ages 18–64, the program offers clinician visits for $49 per visit, with GLP-1 medications billed separately, positioned against competitors like Weight Watchers (up to about $149 per month plus medication) and Noom (starting around $129 per month). Walgreens also lists Wegovy prices starting at $149 per month for 1.5 mg and 4 mg tablets and $199 per month for lower-dose injectables. Demand is significant: about one in eight adults report currently taking a GLP-1 for weight loss or chronic conditions. However, affordability is a major constraint. About half of GLP-1 users report difficulty paying, and less than one in four employers cover GLP-1s for weight loss, highlighting cost access as a defining industry factor.
• February 2026 data signal a cautious consumer backdrop with implications for the US diet and weight-reduction industry. The University of Michigan Index of Consumer Sentiment was 56.6, down 12.5% year-over-year and about 13% below a year ago, while 46% of consumers cited high prices eroding personal finances, above 40% for seven straight months. Although The Conference Board's Consumer Confidence Index edged up to 91.2, it remains well below its November 2024 peak of 112.8. Income expectations improved slightly (17.3% expect increases; 12.3% expect declines), but views of family finances retreated, and spending plans skew toward “cheap thrills and necessary services.” With consumers focused on inflation (year-ahead expectations 3.4%) and cost control, demand may shift toward lower-cost diet options and essential health services, pressuring premium weight-loss programs while favoring value-oriented, results-driven offerings.

• Sales for the US diet and weight reducing industry are projected to grow at a CAGR of 1.94% between 2025 and 2029, slower than the overall economy‘s anticipated growth, according to a forecast from Inforum and the Interindustry Economic Research Fund, Inc. Weight loss services are in the “other services” sector, driven by consumer spending and business expenditure. Consumer sentiment is expected to improve in the forecast period, which bodes well for the industry. Real disposable income is expected to rise 1.8% in 2025 and 1.6% in 2026, limited by a slow rise of employment and higher consumption prices.
• According to Gallup’s National Health and Well-Being Index, the US adult obesity rate has declined from 39.9% in 2022 to 37.0% in 2025, representing 7.6 million fewer obese adults in a shifting weight loss landscape. This shift coincides with a surge in GLP-1 injectable use for weight loss, rising from 5.8% to 12.4% since early 2024. For the weight loss program industry, this trend signals a competitive shift as consumers increasingly turn to pharmaceutical solutions like semaglutide (Ozempic, Wegovy). Traditional programs can adapt by integrating medical weight management options or emphasizing lifestyle support. Usage is highest among adults aged 50–64 (17.0%) and 40–49 (16.2%), who also saw the largest drops in obesity rates. With 89% of Americans now aware of GLP-1s and 13 states covering them under Medicaid, accessibility is expanding. However, diabetes diagnoses continue to rise, underscoring the need for holistic approaches beyond medication.